Skip to content
The Intraday Markets
Pulse

Briefings

Morning BriefOvernight tape and the setup for the openMid-Morning UpdateWhat changed after the opening bell

Markets

Market DashboardTape, movers, watchlist, and cross-asset contextPre-Market SheetOvernight setup, futures, and early moversGlobal SessionsInternational clocks and index performanceInsider ActivityLatest reported executive transactions

LMAT Research

Price ChartTechnical charting and drawing workspaceFundamentals ChartCompare financial metrics across timeCompany OverviewA visual snapshot of company performanceFinancial StatementsPrice, filings, key statistics, and news

Newsletter

Morning Production ReportRanked stories, charts, and newsletter readiness

Financial Statements

Explore

Markets, briefings, and company research

LMAT
Pulse

Briefings

MorningMid-Morning

Markets

DashboardPre-MarketGlobalInsiders

LMAT Research

ChartFundamentalsOverviewFinancials

Newsletter

Morning Report

Newsletter operations and account tools are available from your profile menu after sign-in.

LMAT

$82.38
+$0.45 (0.55%)+0.55%
Closed
Loading chart...
IndexN/A
Market Cap1.88B
Enterprise Value1.99B
Income$0.01B
Sales$0.06B
EmployeesN/A
P/E30.29
P/S7.36
P/B4.67
P/C24.65
EV/EBITDA21.96
EV/SalesN/A
EPS (ttm)2.72
EarningsN/A
Gross Margin71.53%
Oper. Margin27.21%
Profit Margin23.13%
Volume0.55M
Shs Outstand0.02B
Change0.55%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
Income Statement by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Revenue$219.86M$193.48M$161.65M$154.42M$129.37M$117.23M$105.57M$100.87M
Cost of Revenue$68.96M$66.44M$56.76M$53.04M$44.75M$37.38M$31.63M$30.17M
Gross Profit$150.90M$127.05M$104.90M$101.38M$84.62M$79.85M$73.94M$70.70M
Gross Margin68.63%65.66%64.89%65.65%65.41%68.12%70.04%70.09%
Operating Expenses$98.64M$90.34M$78.07M$64.96M$55.83M$58.67M$45.73M$49.59M
Operating Income$52.26M$36.71M$26.83M$36.42M$28.79M$21.18M$28.21M$21.10M
Operating Margin23.77%18.97%16.60%23.59%22.25%18.07%26.72%20.92%
Net Income$44.04M$30.11M$20.64M$26.91M$21.22M$17.93M$22.94M$17.18M
Net Margin20.03%15.56%12.77%17.42%16.40%15.30%21.73%17.03%
EPS (Basic)$1.96$1.36$0.94$1.27$1.05$0.91$1.18$0.91
EBITDAN/AN/AN/AN/AN/AN/AN/AN/A
Stock Option Compensation ExpenseN/AN/AN/AN/AN/AN/AN/AN/A
Price To Earnings RatioN/AN/AN/AN/AN/AN/AN/AN/A
Price To Sales RatioN/AN/AN/AN/AN/AN/AN/AN/A
Shares OutstandingN/AN/AN/AN/AN/AN/AN/AN/A
Market CapitalizationN/AN/AN/AN/AN/AN/AN/AN/A
Balance Sheet by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Cash & Short Term InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Short Term ReceivablesN/AN/AN/AN/AN/AN/AN/AN/A
InventoriesN/AN/AN/AN/AN/AN/AN/AN/A
Other Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Current AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Net Property, Plant & EquipmentN/AN/AN/AN/AN/AN/AN/AN/A
Total Investments and AdvancesN/AN/AN/AN/AN/AN/AN/AN/A
Long-Term Note ReceivableN/AN/AN/AN/AN/AN/AN/AN/A
Intangible AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Other AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Total Assets$551.82M$346.78M$310.48M$292.80M$252.81M$188.34M$153.09M$126.32M
Short Term Debt Incl. Current Port. of LT DebtN/AN/AN/AN/AN/AN/AN/AN/A
Accounts PayableN/AN/AN/AN/AN/AN/AN/AN/A
Income Tax PayableN/AN/AN/AN/AN/AN/AN/AN/A
Other Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Current LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Provision for Risks ChargesN/AN/AN/AN/AN/AN/AN/AN/A
Deferred Tax LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Other LiabilitiesN/AN/AN/AN/AN/AN/AN/AN/A
Total Liabilities$214.53M$48.88M$42.27M$38.65M$80.24M$40.20M$22.85M$16.55M
Non-Equity ReservesN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Stock - Carrying ValueN/AN/AN/AN/AN/AN/AN/AN/A
Common EquityN/AN/AN/AN/AN/AN/AN/AN/A
Total Shareholders Equity$337.29M$297.90M$268.20M$254.15M$172.57M$148.14M$130.24M$109.77M
Accumulated Minority InterestN/AN/AN/AN/AN/AN/AN/AN/A
Total Equity$337.29M$297.90M$268.20M$254.15M$172.57M$148.14M$130.24M$109.77M
Total Liabilities & Stockholders Equity$551.82M$346.78M$310.48M$292.80M$252.81M$188.34M$153.09M$126.32M
Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Tangible Book Value Per ShareN/AN/AN/AN/AN/AN/AN/AN/A
Full-Time EmployeesN/AN/AN/AN/AN/AN/AN/AN/A
Price to Book RatioN/AN/AN/AN/AN/AN/AN/AN/A
Return on AssetsN/AN/AN/AN/AN/AN/AN/AN/A
Return on EquityN/AN/AN/AN/AN/AN/AN/AN/A
Return on Invested CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/AN/AN/AN/A
Cash Flow by fiscal year, newest to oldest
MetricFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Net Income$44.04M$30.11M$20.64M$26.91M$21.22M$17.93M$22.94M$17.18M
DepreciationN/AN/AN/AN/AN/AN/AN/AN/A
Other Funds (Non Cash)N/AN/AN/AN/AN/AN/AN/AN/A
Funds from OperationsN/AN/AN/AN/AN/AN/AN/AN/A
Extraordinary ItemN/AN/AN/AN/AN/AN/AN/AN/A
Changes in Working CapitalN/AN/AN/AN/AN/AN/AN/AN/A
Income Taxes PayableN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Operating Activities$44.12M$36.75M$25.38M$35.10M$34.80M$14.18M$19.51M$22.87M
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/AN/A
Net Assets From AcquisitionsN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Fixed Assets and BusinessesN/AN/AN/AN/AN/AN/AN/AN/A
Purchase or Sale of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Purchase of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Sale Or Maturity of InvestmentsN/AN/AN/AN/AN/AN/AN/AN/A
Other UsesN/AN/AN/AN/AN/AN/AN/AN/A
Other SourcesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Investing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Cash Dividends PaidN/AN/AN/AN/AN/AN/AN/AN/A
Change in Capital StockN/AN/AN/AN/AN/AN/AN/AN/A
Repurchase of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Sale of Common Pref StockN/AN/AN/AN/AN/AN/AN/AN/A
Proceeds from Stock OptionsN/AN/AN/AN/AN/AN/AN/AN/A
Issuance or Reduction of Debt, NetN/AN/AN/AN/AN/AN/AN/AN/A
Change in Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Issuance of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Reduction of Long Term DebtN/AN/AN/AN/AN/AN/AN/AN/A
Net Financing Active Other Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Other Financing Activities UsesN/AN/AN/AN/AN/AN/AN/AN/A
Cash from Financing ActivitiesN/AN/AN/AN/AN/AN/AN/AN/A
Exchange Rate EffectN/AN/AN/AN/AN/AN/AN/AN/A
Net Change in CashN/AN/AN/AN/AN/AN/AN/AN/A
Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A
Preferred Dividends (Cash Flow)N/AN/AN/AN/AN/AN/AN/AN/A
Price to Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/A

Company coverage

Latest news

20 stories
May 5 · 8:05PMLeMaitre Q1 2026 Financial ResultsBenzinga ↗Mar 28 · 12:06AMLeMaitre Vascular Up 30% as Insider Sells $285K in Stock. Here's What Investors Should KnowThe Motley Fool ↗Feb 27 · 7:50PMLeMaitre to Participate at Upcoming Investor Conferences in MarchGlobeNewswire Inc. ↗Oct 9 · 9:53PMLeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025GlobeNewswire Inc. ↗Aug 6 · 5:09AMLeMaitre (LMAT) Q2 Revenue Jumps 15%The Motley Fool ↗Jun 10 · 2:52AMAnteris Appoints David Roberts and Gregory Moss to its Board of DirectorsGlobeNewswire Inc. ↗Dec 16 · 12:57PMLeMaitre Vascular Announces Proposed Convertible Senior Notes OfferingGlobeNewswire Inc. ↗Nov 1 · 8:47PMLeMaitre to Participate at Upcoming Investor Conferences in NovemberGlobeNewswire Inc. ↗
Show 12 more stories↓
Aug 27 · 8:54PMLeMaitre to Participate at Upcoming Investor Conferences in SeptemberGlobeNewswire Inc. ↗Jul 16 · 9:27PMLeMaitre Will Announce Second Quarter 2024 Earnings Results August 1, 2024 - GlobeNewswireGlobeNewswire Inc. ↗Jul 1 · 1:25PMMerit Medical (MMSI) Hits 52-Week High: What's Aiding It?Zacks Investment Research ↗Jun 27 · 4:49PMGlaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?Zacks Investment Research ↗Jun 26 · 5:41PMIntuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?Zacks Investment Research ↗Jun 26 · 5:29PMEncompass Health (EHC) Expands in Louisville With New Rehab UnitZacks Investment Research ↗Jun 25 · 4:46PMGE HealthCare's (GEHC) New Tie-Up to Boost CVD WorkflowZacks Investment Research ↗Jun 24 · 5:50PMEncompass Health (EHC) Gains 30% in a Year: More Room to Run?Zacks Investment Research ↗Jun 21 · 4:00PMLeMaitre (LMAT) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research ↗Jun 21 · 11:26AMNew Strong Buy Stocks for June 21stZacks Investment Research ↗Jun 11 · 4:31PMHumana's (HUM) CenterWell Sets Foot in Asheville With New CentersZacks Investment Research ↗Jun 1 · 5:00AMMy Dividend Growth PortfolioSeeking Alpha ↗

Insider Trading

View All
Insider
Type
Shares
Price
Value
Date
BRIDGET A ROSS
Sell
4.3K
$103.94
$449K
Jul 29, 26
LeMaitre George W
Gift
12.0K
—
—
Jun 4, 26
Kamke Trent G
Award
1.682
—
—
Jun 4, 26
Roberts David B
Award
3.734
—
—
Jun 4, 26
LeBlanc Dorian Paul
Award
2.476
—
—
Jun 4, 26

Company

CEO: George W. LeMaitreEmployees: 651www.lemaitre.com
About the company↓

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

Discover more

You may be interested in
MSFT

Microsoft Corp

$495.40

↓ 0.33%
ABX

Abacus Global Management Inc

$9.27

↑ 8.80%
META

Meta Platforms Inc

$589.85

↓ 0.79%
NFLX

Netflix Inc

$78.16

↑ 0.11%
DIS

Walt Disney Co

$106.85

↑ 2.10%
AMD

Advanced Micro Devices

$514.39

↑ 6.79%
TSLA

Tesla Inc

$342.27

↑ 0.49%
BAC

Bank of America Corp

$64.49

↑ 0.61%
ADBE

Adobe Inc

$264.02

↓ 2.40%
ORCL

Oracle Corp

$150.52

↓ 3.49%
PYPL

PayPal Holdings Inc

$61.66

↑ 2.21%
NVDA

NVIDIA Corp

$225.16

↓ 0.24%
The Intraday Markets

© 2026 The Intraday. All rights reserved.

Market data may be delayedFor informational purposes onlyFMP · Massive · SEC